Third, while identification of naïve and memory B cells requires sophisticated cytometry panels and is not standardized across laboratories, measurement of CD19+ B cells is easily reproducible and widely used in haematological and immunological settings, representing a cheap and readily available biomarker for predicting disease outcomes also in IgG4-RD. This evidence concerns the gene CD19 and immunoglobulin G4-related sclerosing disease.